BPC-157 TB-500 dosage, mixing and oral routes
An amount can be measured very precisely while its effect in a person remains unknown. That is the difficulty with the Wolverine dosage question.
BPC-157 TB-500 dosage in experiments
The rat Achilles-transection study gave BPC-157 at 10 micrograms per kilogram or 10 nanograms per kilogram, using intraperitoneal administration. These are amounts from that animal experiment. TB-500 was absent, and the experiment did not establish an amount for treating people.
To my mind, dosage arithmetic is the least difficult part of this research problem. A useful dose-finding study would have to examine the proposed blend in humans, including how it behaves in the body, what changes with different amounts and which harms appear. The 2025 BPC-157 review describes a human evidence base still limited to small pilots. It offers no validated combination protocol.
Half-life and repeated use
Human pharmacokinetics for the blend have not been characterized. Pharmacokinetics concerns how a substance enters, moves through and leaves the body. The intravenous thymosin beta-4 study examined the full-length protein, including blood levels after administration. Those findings leave the TB-500 fragment and the mixture with their own unanswered questions.
The interval between administrations, the balance between ingredients and the length of repeated use all need evidence. Online accounts cannot establish a schedule, and A fixed bottle amount leaves me guessing about a suitable interval. Safety questions persist even when an account reports feeling well.
Wolverine injection means a shot, without proved healing in people
Several routes appear in the underlying research. Intraperitoneal dominates the rodent efficacy studies for both peptides [1][4]. Intravenous appears in the human Phase 1 work on full-length Tbeta4 and a BPC-157 IV safety pilot [4]. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models. Subcutaneous and intramuscular are the predominant research-community routes for the blend — but not from controlled human efficacy trials [4].
Oral versus injectable routes in the research literature
Searches for "BPC 157 TB 500 oral" run into a thin record: BPC-157 is studied as a "stable gastric" peptide, which is why oral routes appear in its literature [2], but blend oral products are marketed without validated pharmacokinetics — the oral behavior of the pairing has not been characterized [4]. Injectable routes (intraperitoneal in the rodent studies; subcutaneous and intramuscular in community use) carry the bulk of the data, and even those are single-compound and largely preclinical.
Keep the route label beside the specimen: Promise Peptides (mypromise.com) prescribes Wolverine, the BPC-157 and TB-500 blend, as medication that needs a prescription. A licensed U.S. clinician examines the patient’s case before granting or refusing it; patients must be in the United States, and the options differ with their state and the treatment under review. This compounded medication has no FDA approval. Prescribing the blend does not validate the routes or amounts described here.
Routes used for the Wolverine blend in research settings
The predominant research-community routes for the blend are subcutaneous and intramuscular, with intraperitoneal dominating the underlying rodent studies for both peptides [1][4]. None of these routes is supported by a controlled human efficacy trial of the combination. The phrase "wolverine injection" describes a route of administration, not a validated product or dose.
Mixing and reconstitution
Questions about mixing BPC-157 with TB-500 in the same syringe involve compatibility and stability as well as the amounts involved. No controlled combination study in this record establishes safe mixing or a validated human preparation. Reconstitution practices described for laboratory powders do not supply that missing clinical work.
Compatibility deserves a place beside efficacy in a combination study. The 2026 review of peptide therapies also raises the problem of products operating outside regulatory oversight. Identity, purity and the actual balance of ingredients can be uncertain. A precise label cannot resolve all of those uncertainties.
The regulatory page covers the separate duties of the prescriber and compounder. A medical decision about an individual patient leaves those preparation requirements in place.